Earnshaw SR, Mullins CD, Brogan AJ, Wolowacz SE. Budget impact analysis: applications and design issues. Presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. Previously presented at the 2014 ISPOR 19th Annual International Meeting.
Brogan AJ, Smets E, Mauskopf JA, Manuel SA, Adriaenssen I. Cost-effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada. Pharmacoeconomics. 2014 Sep;32(9):903-17.
Wilkins E, Fisher M, Brogan AJ, Talbird SE. An analysis of cost and health outcomes associated with tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the United Kingdom. Poster presented at the 20th International AIDS Conference; July 20, 2014.
Mauskopf JA, Mullins CD, Earnshaw SR, Brogan AJ. Budget impact analysis: applications and design issues. Presented at the 2014 ISPOR 19th Annual International Meeting; June 1, 2014. Montreal, Canada.
Wilkins E, Fisher M, Brogan AJ, Talbird SE. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV-1 infection in the United Kingdom. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014. [abstract] Value Health. 2014 May; 17(3):A276.
Brogan AJ, Talbird SE, Thompson JR, Miller JD, Rubin J, Deniz B. Cost-effectiveness of telaprevir combination therapy for chronic hepatitis C. PLoS One. 2014 Mar 6;9(3):e90295. doi: 10.1371/journal.pone.0090295
Brogan AJ, Stidham S. Portfolio optimization risk measures: variance versus target semivariance. Presented at the Annual Meeting of the Institute for Operations Research and Management Science; November 2002.